1. European expert opinion on the management of invasive candidiasis in adults 
B.J. Kullberg, P.E. Verweij, M. Akova, M.C. Arendrup, J. Bille, T. Calandra, M. Cuenca-Estrella, R. Herbrecht, F. Jacobs, M. Kalin, C.C. Kibbler, O. Lortholary, P. Martino, J.F. Meis, P. Muñoz, F.C. Odds, B.E. De Pauw, J.H. Rex, E. Roilides, T.R. Rogers, M. Ruhnke, A.J. Ullmann, Ö. Uzun, K. Vandewoude, J.-L. Vincent, J.P. Donnelly 
Clinical Microbiology and Infection 
Volume 17, Pages 1-12 (September 2011)
DOI: /j x
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Responses to the questions on initial treatment of candidaemic patients (a) uncomplicated; (b) received fluconazole previously during this admission.
Clinical Microbiology and Infection  , 1-12DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
Responses to the questions on initial treatment of candidaemic patients: (a) in the intensive-care unit (ICU) with severe sepsis, unstable or moderately to severely ill; (b) neutropenic haematology patient without azole prophylaxis.
Clinical Microbiology and Infection  , 1-12DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3
Responses to the questions on treatment of candidaemic patients (a) infected with fluconazole-susceptible Candela globrata; (b) infected with Candida krusei; or (c) infected with Candida parapsiosis and clinically responding to initial therapy with an echinocandin.
Clinical Microbiology and Infection  , 1-12DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions